The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.

There are many exciting developments in the field of midlife women’s health which explain how menopause symptoms, particularly hot flashes, may be an important vital sign and predictor of future health status. Additionally, in the therapeutic realm, there is a new class of medications that affect the thermoregulatory channels in the brain that control vasomotor symptoms (VMS). This development may unlock treatment options for women who cannot tolerate or cannot safely take hormone therapy.

Contraception encompasses the concept of avoiding a pregnancy, and is aimed at women of reproductive age who, although are sexually active, do not want to achieve any pregnancy at their option fertility preservation and family planning. It should be underlined that no method of contraception is 100% guaranteed because its success depends on many factors such as patient’s compliance to gynecologists instructions, woman’s age, the advantages and disadvantages of each method, the frequency of sexual intercourse and of course the type of contraception.

Intentional facial expression of emotion named facial mimic is critical to healthy social interactions. Psychological and functional implications of the facial paralysis present a devastating management problem to patients afflicted because their face have an important challenge of facial muscles that are fundamental also for affective communication.

We recently published our multi-institutional experience performing primary robot-assisted retroperitoneal lymph node dissection (RA-RPLND) for men with non-seminomatous germ cell tumor (NSGCT). We concluded that primary RA-RPLND for NSGCT can be performed safely with low complication rates, acceptable early oncologic outcomes, and lower overall theoretical chemotherapy burden. In this commentary, we explore outcomes in clinical stage I patients stratified by clinical risk factors (RF) and estimate reductions in chemotherapy burden.